BR9712951A - Processo para piridinas substituìdas - Google Patents

Processo para piridinas substituìdas

Info

Publication number
BR9712951A
BR9712951A BR9712951-8A BR9712951A BR9712951A BR 9712951 A BR9712951 A BR 9712951A BR 9712951 A BR9712951 A BR 9712951A BR 9712951 A BR9712951 A BR 9712951A
Authority
BR
Brazil
Prior art keywords
amino
substituted pyridines
nitro
processes
formula
Prior art date
Application number
BR9712951-8A
Other languages
English (en)
Inventor
Keith Michael Devries
Robert Lee Dow
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9712951A publication Critical patent/BR9712951A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção:<B>"PROCESSO PARA PIRIDINAS SUBSTITUìDAS"<D>. Esta invenção refere-se a processos para a preparação de compostos da fórmula (I) que são <225> agonistas receptores adrenérgicos, e a processos para a preparácão de certos intermediários da fórmula (IIA) em que R^ 1^ é nitro, amino ou amino protegido; R^ 2^ é H, flúor, cloro, CF~ 3~, nitro, alquila C~ 1~ -C~ 4~ alcóxi C~ 1~- C~ 4~ , amino ou amino protegido; e X^ 1^ é OH ou um grupo de saída adequado, usados naquele processo. A invenção refere-se a novos compostos das fórmulas (II).
BR9712951-8A 1996-11-14 1997-11-03 Processo para piridinas substituìdas BR9712951A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14
PCT/IB1997/001367 WO1998021184A1 (en) 1996-11-14 1997-11-03 Process for substituted pyridines

Publications (1)

Publication Number Publication Date
BR9712951A true BR9712951A (pt) 1999-12-07

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712951-8A BR9712951A (pt) 1996-11-14 1997-11-03 Processo para piridinas substituìdas

Country Status (32)

Country Link
US (1) US6291489B1 (pt)
EP (1) EP0938476B1 (pt)
JP (1) JP3510635B2 (pt)
KR (1) KR20000053314A (pt)
CN (1) CN1237160A (pt)
AP (1) AP805A (pt)
AR (1) AR010584A1 (pt)
AT (1) ATE319687T1 (pt)
AU (1) AU4634697A (pt)
BG (1) BG103393A (pt)
BR (1) BR9712951A (pt)
CA (1) CA2270386C (pt)
CO (1) CO4930261A1 (pt)
DE (1) DE69735433D1 (pt)
EA (1) EA199900375A1 (pt)
GT (1) GT199700118A (pt)
HR (1) HRP970612A2 (pt)
ID (1) ID18898A (pt)
IL (1) IL129688A0 (pt)
IS (1) IS5029A (pt)
MA (1) MA24401A1 (pt)
MY (1) MY132507A (pt)
NO (1) NO992296L (pt)
OA (1) OA11044A (pt)
PA (1) PA8441401A1 (pt)
PE (1) PE10299A1 (pt)
TN (1) TNSN97172A1 (pt)
TR (1) TR199901063T2 (pt)
UY (1) UY24774A1 (pt)
WO (1) WO1998021184A1 (pt)
YU (1) YU22099A (pt)
ZA (1) ZA9710186B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052892A2 (en) * 1998-04-08 1999-10-21 Novartis Ag Novel herbicides
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
AU2571300A (en) * 1999-02-16 2000-09-04 Kaneka Corporation Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
DE60015036T2 (de) * 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
US20040265991A1 (en) * 2001-10-17 2004-12-30 Naoaki Taoka Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives
WO2003072547A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. PROCESSES AND INTERMEDIATES USEFUL IN PREPARING β3-ADRENERGIC RECEPTOR AGONISTS
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
WO2003072573A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
RU2313524C2 (ru) 2003-05-09 2007-12-27 Ф.Хоффманн-Ля Рош Аг МИТИЛИНДОЛЫ И МЕТИЛПИРРОЛОПИРИДИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ α-1-АДРЕНЕРГИЧЕСКИХ АГОНИСТОВ
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
BR9406823A (pt) * 1993-06-14 1996-03-26 Pfizer Aminas secundárias e agentes anti-diabéticos e antiobesidade
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
WO1996035670A1 (en) 1995-05-10 1996-11-14 Pfizer Inc. β-ADRENERGIC AGONISTS
US5977124A (en) * 1995-05-10 1999-11-02 Pfizer Inc. β-adrenergic agonists

Also Published As

Publication number Publication date
AU4634697A (en) 1998-06-03
MY132507A (en) 2007-10-31
US6291489B1 (en) 2001-09-18
CN1237160A (zh) 1999-12-01
JP2000504347A (ja) 2000-04-11
ID18898A (id) 1998-05-20
PA8441401A1 (es) 2000-05-24
NO992296D0 (no) 1999-05-12
IL129688A0 (en) 2000-02-29
AP805A (en) 2000-01-28
IS5029A (is) 1999-04-16
ATE319687T1 (de) 2006-03-15
CO4930261A1 (es) 2000-06-27
DE69735433D1 (de) 2006-05-04
EA199900375A1 (ru) 1999-12-29
CA2270386C (en) 2004-08-03
HRP970612A2 (en) 1998-08-31
OA11044A (en) 2002-02-20
AP9701147A0 (en) 1998-01-31
JP3510635B2 (ja) 2004-03-29
EP0938476A1 (en) 1999-09-01
YU22099A (sh) 2001-09-28
KR20000053314A (ko) 2000-08-25
BG103393A (en) 2000-07-31
ZA9710186B (en) 1999-05-12
MA24401A1 (fr) 1998-07-01
CA2270386A1 (en) 1998-05-22
AR010584A1 (es) 2000-06-28
TR199901063T2 (xx) 1999-08-23
TNSN97172A1 (fr) 2005-03-15
EP0938476B1 (en) 2006-03-08
GT199700118A (es) 1999-05-05
PE10299A1 (es) 1999-02-10
UY24774A1 (es) 1998-05-05
NO992296L (no) 1999-05-12
WO1998021184A1 (en) 1998-05-22

Similar Documents

Publication Publication Date Title
BR9712951A (pt) Processo para piridinas substituìdas
BR0212733A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
BR9714155A (pt) Prevenção da perda e reposição da massa óssea por certos agonistas de prostaglandina.
BR9804437A (pt) Compostos para a osteoporose
PT1237553E (pt) Combinacao de um inibidor de recaptacao da serotonina e de um antagonista, de um agonista inverso ou de um agonista parcial para o 5-ht2c
HUP0203509A2 (hu) Triciklusos pirazolkarbonsav-származékok, a vegyületek előállítása és a vegyületeket tartalmazó gyógyászati készítmények
BR9814300A (pt) Método de preparação de óxidos de tetraidrobenzotiepina enanciomericamente enriquecidos
BR0208179A (pt) Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto
BR9812371A (pt) Tratamento de distúrbio de conduta
BR9915381A (pt) Uso de um composto, e, composto
BR9813989A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição
BR9810829A (pt) Composto, processo para preparar o mesmo, composição, uso de um composto ou um sal farmaceuticamente aceitável do mesmo ou uma composição, e, processo de tratamento de uma condição
ID18883A (id) Pesaing 5-ht 1f
BR9811301A (pt) Processo para preparar brometos de benzila substituìdos
BR9911137A (pt) Processo para tratamento de correntes de fluido
BR9812357A (pt) Tratamento de distúbio oposicional desafiador
BR0207645A (pt) Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos
BR0016952A (pt) Compostos derivados de fenil-piperazina substituìdos, composição farmacêutica, uso e método
BR9909555A (pt) Herbicidas
BR0207673A (pt) Compostos de carbamato para o uso no tratamento de dor
BR0213561A (pt) Processo para a preparação de amidas de ácido 2-halopiridincarboxìlico
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
FI952094A0 (fi) Ihmisen serotoniinireseptoria (5-HT4B)koodaava DNA ja sen käyttö
BR0207830A (pt) Compostos de carbamato para uso em prevenir ou tratar distúrbios de ansiedade
BR9907425A (pt) Compostos de aminas estericamente impedidas

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements